About The Journal Open Access
Journal of Cardiovascular Medicine and Therapeutics is committed to dispersing unique and top-level original research articles, letters, perspectives, opinions, commentaries, case reports, reviews, letter to editor, editorials, and short communications etc. in every aspect of cardiovascular medicine.
The segment Cardiovascular Therapeutics is additionally concerned with the identification and validation of biomarkers to either help drug improvement, or permit a stratified medicine approach in patients. Biomarkers may identify with physiological measures,heredity qualities, or any of the developing advancements.
Aims and scope
Journal of Cardiovascular Medicine and Therapeutics gives dependable data upgrade to online viewers with the adapted methods and most advancement in the field of cardiovascular medicine and therapeutics. The editor’s welcome articles of current interest on research across all ranges of cardiovascular disease including; arteriosclerosis, cardiomyopathies, coronary artery disease, diabetes, heart disappointment, hypertension, metabolic syndrome, obesity, peripheral arterial disease, stroke, arrhythmias, and genetics.
Journal of Cardiovascular Medicine and Therapeutics is a peer reviewed, scholarly journal that gives a gathering to the most developed research and refined advancements in the field of ischemic coronary illness, congestive heart failure, pharmacological and non-pharmacological treatment, cardiomyopathy, valvular heart disease, vascular disease, cardiovascular science, prosthetic devices, hypertension, arrhythmia, congenital heart disease, preventive cardiology, new diagnostic techniques, cardiovascular imaging and exploratory models of cardiovascular disease.
You may send the article online at www.scholarscentral.org/submissions/cardiovascular-medicine-therapeutics.html or as an email attachment to the mail-id firstname.lastname@example.org and/or email@example.com
Fast Editorial Execution and Review Process (FEE-Review Process)
Journal of Cardiovascular Medicine and Therapeutics is participating in the Fast Editorial Execution and Review Process (FEE-Review Process) with an additional prepayment of $99 apart from the regular article processing fee. Fast Editorial Execution and Review Process is a special service for the article that enables it to get a faster response in the pre-review stage from the handling editor as well as a review from the reviewer. An author can get a faster response of pre-review maximum in 3 days since submission, and a review process by the reviewer maximum in 5 days, followed by revision/publication in 2 days. If the article gets notified for revision by the handling editor, then it will take another 5 days for external review by the previous reviewer or alternative reviewer.
Acceptance of manuscripts is driven entirely by handling editorial team considerations and independent peer-review, ensuring the highest standards are maintained no matter the route to regular peer-reviewed publication or a fast editorial review process. The handling editor and the article contributor are responsible for adhering to scientific standards. The article FEE-Review process of $99 will not be refunded even if the article is rejected or withdrawn for publication.
The corresponding author or institution/organization is responsible for making the manuscript FEE-Review Process payment. The additional FEE-Review Process payment covers the fast review processing and quick editorial decisions, and regular article publication covers the preparation in various formats for online publication, securing full-text inclusion in a number of permanent archives like HTML, XML, and PDF, and feeding to different indexing agencies.